A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Inclusion Criteria: Adults 18 years or older Newly diagnosed glioblastoma (Within 2 months of initial diagnosis by histopathology) Not started standard of care chemotherapy and/or radiation therapy for glioblastoma Karnofsky Performance Status (KPS) ≥ 70 Ability to read, write and understand either English OR Spanish Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: Patients with recurrent glioblastoma Genetic disorders that affect lipid metabolism. Including but not limited to pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects Inability to wean steroids below 8mg dexamethasone / day or equivalent Body Mass Index (BMI) < 21kg/m2, unless the site Principal Investigator deems safe Currently pregnant or nursing Patients receiving other experimental therapy Note: Off-label therapy use is permitted Comorbidities that in the opinion of the investigator limit the patient's ability to complete the study Food preferences incompatible with keto diet Using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants (removable hearing aids permitted), or other electronic medical equipment, unless the site Principal Investigator deems safe Inability to participant in standard of care MRIs